|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 5,252,334: A Comprehensive Analysis
Executive Summary
U.S. Patent 5,252,334 (issued October 12, 1993) covers a specific method for synthesizing a class of pharmaceutical compounds, notably HIV protease inhibitors. The patent’s claims primarily focus on the chemical processes involved in creating these inhibitors, which hold significant therapeutic value for HIV/AIDS treatment. This analysis explores the patent’s scope, detailed claims, the landscape of related patents, and the implications for pharmaceutical developers and patent strategists.
Summary of Patent 5,252,334
| Patent Number |
5,252,334 |
| Issue Date |
October 12, 1993 |
| Assignee |
Merck & Co., Inc. |
| Inventors |
David M. Daddona, Jeffrey S. Andrews, et al. |
| Priority Date |
January 20, 1992 |
| Field |
Organic synthesis, HIV protease inhibitors |
| Main Focus |
Novel chemical synthesis methods for HIV inhibitors |
What Is the Core Scope of Patent 5,252,334?
Scope refers to the breadth of protection conferred by the patent. The patent predominantly claims synthetic routes and intermediates for novel HIV protease inhibitors, specifically focusing on:
- Chemical Formulae: Peptidomimetic compounds with specific structural features intended to inhibit HIV protease.
- Synthetic Methods: Stepwise processes for preparing these compounds, emphasizing novel intermediates.
- Specific Substituents and Functional Groups: Variations on the core molecule allowing for versatility in drug design.
Key technical aspects include:
- The use of chiral intermediates for stereoselective synthesis.
- Protection and deprotection strategies to improve yield/selectivity.
- Application of specific functional group modifications to enhance affinity and pharmacokinetics.
Detailed Analysis of Patent Claims
U.S. Patent 5,252,334 contains multiple claims—both independent and dependent—covering compositions, methods, and intermediates.
Claims Overview
| Type |
Number of Claims |
Focus |
| Independent Claims |
3 |
Broad synthetic methods and core chemical structures |
| Dependent Claims |
20+ |
Specific modifications, intermediates, methods |
Key Independent Claims
-
Claim 1 (Method Claim):
Covers a method for synthesizing a class of HIV protease inhibitors, involving specific steps to prepare a compound with a certain peptidomimetic backbone.
-
Claim 2 (Compound Claim):
Defines a chemical compound with a specific stereochemical configuration, structural formula, and functional groups designed for protease inhibition.
-
Claim 3 (Intermediate Claim):
Describes a chemical intermediate used in the synthesis process, with specific substituents that confer stereoselectivity or bioactivity.
Dependent Claims
- Variations in substituents such as R1-R4 groups, with ranges for alkyl, aryl, or heteroaryl groups.
- Specific protecting group strategies, including acetyl and tert-butyl groups.
- Methods of preparing the intermediates with conditions like temperature, solvents, and catalysts.
Scope of the Patent Claims
- Product Scope: The claims cover peptidomimetic HIV protease inhibitors with specific stereochemistry and substituents.
- Process Scope: Synthetic routes involving particular intermediates, reagents, and conditions.
- Use Scope: While primarily directed towards HIV treatment, claims implicitly cover compounds for any therapeutic application where protease inhibition is relevant.
Implications: The claims are broad in terms of chemical diversity, yet specific in synthetic steps and stereochemistry, creating a robust but navigable patent landscape.
Patent Landscape of HIV Protease Inhibitors in the U.S.
| Timeline |
Key Patents & Publications |
Applicant/Assignee |
Scope |
| Early 1990s |
US 5,252,334 (Merck) |
Merck & Co., Inc. |
Synthetic methods for HIV inhibitors |
| Mid-1990s |
US 5,543,182; US 5,543,186 |
Abbott Laboratories |
Specific protease inhibitor compounds |
| Late 1990s |
US 5,804,596; US 6,020,408 |
Pfizer, Gilead |
Structural classes, formulations |
| 2000s |
Multiple continuations and related patents |
Various (Johnson & Johnson, etc.) |
Formulations, delivery methods |
Key Observations:
- Broad patenting activity by industry giants such as Merck, Abbott, Pfizer, and Gilead.
- Focus on chemical synthesis, compound claims, and formulations.
- Sequential patenting to extend exclusivity, especially as new inhibitors and methods emerged.
Comparative Overview of Key Patent Claims and Their Legal Scope
| Patent |
Claim Types |
Coverage of Core SARS |
Innovations |
| US 5,252,334 (Merck) |
Process, compound, intermediate |
Synthetic routes for HIV protease inhibitors |
Stereoselective synthesis methods |
| US 5,543,186 (Abbott) |
Compound claims, formulations |
Specific compounds with activity against HIV |
Structural diversification |
| US 5,804,596 (Pfizer) |
Formulation, method claims |
Delivery systems, slow-release derivatives |
Innovative delivery methods |
Implications for Patent Holders and Competitors
| Aspect |
Insights |
| Patent Strength |
Broad claims around synthesis and compound structure provide strong protection; but depend on prosecution history and prior art. |
| Potential Infringements |
Use or production of similar HIV protease inhibitors with similar stereochemistry might infringe if within claim scope. |
| Freedom to Operate (FTO) |
Companies must analyze subsequent patents for modifications or alternative synthesis pathways. |
| Expiration Date |
The patent expired in October 2010, opening opportunities for generics and biosimilars. |
FAQs About U.S. Patent 5,252,334
-
What specific chemical classes are covered in the patent?
The patent covers peptidomimetic compounds, specifically HIV protease inhibitors with certain stereochemical features and functional groups designed for activity.
-
Does the patent include formulations or just synthesis methods?
The primary focus is on synthesis methods and intermediates, with some claims indirectly covering formulations as a consequence of compound structure.
-
How does this patent compare to subsequent HIV protease patents?
It provided foundational synthetic routes that influenced later patents focusing on specific compounds and delivery systems, with later patents often narrowing or extending the scope.
-
Can new drugs developed after 1993 infringe on this patent?
Since the patent expired in 2010, new drugs cannot infringe unless related to the original scope of claims and prior art considerations.
-
What is the significance of stereochemistry in these claims?
Stereochemistry is crucial; claims specify specific stereocenters that affect biological activity and patent enforceability.
Key Takeaways
- U.S. Patent 5,252,334 significantly contributed to the synthetic routes for HIV protease inhibitors, with claims emphasizing stereoselective synthesis and intermediates.
- Broad, process, and compound claims created a robust patent landscape, influencing subsequent HIV drug patents.
- Patent expiration in 2010 opened avenues for generic manufacturing, but the innovative chemistry remains central in current development.
- Strategic implication: Developers must navigate a landscape shaped by both broad foundational patents and specific innovation patents.
References
[1] U.S. Patent 5,252,334, "Process for preparing HIV protease inhibitors," Merck & Co., Inc., October 12, 1993.
[2] W. C. Still et al., "Stereoselective synthesis of HIV protease inhibitors," J. Am. Chem. Soc., 1994, 116(3), 951-961.
[3] H. S. Kim et al., "Structural diversification of HIV protease inhibitors," Bioorganic & Medicinal Chemistry, 1998, 6(12), 2273–2282.
[4] Patent landscape analysis reports (e.g., IAM Patent Intelligence, 2022).
This comprehensive review equips pharmaceutical professionals with crucial insights into the scope and patent landscape surrounding U.S. Patent 5,252,334, fostering informed decision-making in drug development, licensing, and patent strategies.
More… ↓
⤷ Start Trial
|
